Press coverage about Bristol-Myers Squibb (NYSE:BMY) has been trending somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0155103089447 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Opdivo In Focus After BMY’s Checkmate-214 Study Being Stopped Early (forbes.com)
- The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 (finance.yahoo.com)
- Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear (investorplace.com)
- Jefferies Group Comments on Bristol-Myers Squibb Company’s FY2017 Earnings (BMY) (americanbankingnews.com)
- SunTrust Banks Brokers Reduce Earnings Estimates for Bristol-Myers Squibb Company (BMY) (americanbankingnews.com)
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 0.35% on Monday, hitting $62.70. The stock had a trading volume of 6,976,468 shares. The firm’s 50 day moving average is $58.77 and its 200-day moving average is $55.98. The stock has a market capitalization of $102.82 billion, a PE ratio of 22.90 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $63.47.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 earnings per share. Equities research analysts expect that Bristol-Myers Squibb will post $2.98 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
Several equities research analysts recently issued reports on BMY shares. Jefferies Group LLC increased their price objective on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price objective for the company in a research note on Wednesday, July 12th. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, BMO Capital Markets reissued an “underperform” rating and issued a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $62.66.
WARNING: “Bristol-Myers Squibb (BMY) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/09/19/bristol-myers-squibb-bmy-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II bought 6,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.